AstraZeneca signs $2 billion agreement with Quell to develop cell therapies

(Reuters) – AstraZeneca said on Friday it had signed an agreement with Quell Therapeutics potentially worth more than $2 billion to develop cell therapies that could cure autoimmune diseases. The agreement includes developing, manufacturing and commercialising cell therapies that have the potential to be curative in type 1 diabetes and inflammatory bowel disease indications, the…

Read More

Odey Asset Management tells investors ‘confident’ banks will continue to work with fund – letter

By Nell Mackenzie LONDON (Reuters) – Odey Asset Management “does not recognise the picture of the firm that has been painted” by allegations of sexual misconduct by Crispin Odey published by media on Thursday, it told investors in a letter seen by Reuters. The letter, dated June 8 and signed by Peter Martin, the company’s…

Read More